AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33713411 — intervention group
Group type: COMPARATOR
Intervention: Black on white warnings (BW)
Number of subjects: 1131
Study 32705319 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-articular infiltration of morphine, ropivacaine, and epinephrine
Number of subjects: 0
Study 32705319 — intervention group
Group type: COMPARATOR
Intervention: Control group with peri-articular infiltration of ropivacaine and epinephrine only
Number of subjects: 0
Study 36042753 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin α1 (Tα1)
Number of subjects: 105
Study 36042753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 32855225 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation powder (TIP) - 84 mg (3 capsules once daily)
Number of subjects: 107
Study 32855225 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation powder (TIP) - 140 mg (5 capsules once daily)
Number of subjects: 107
Study 32855225 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation powder (TIP) - 224 mg (4 capsules twice daily)
Number of subjects: 107
Study 32855225 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous TIP
Number of subjects: 107
Study 32855225 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical TIP
Number of subjects: 107
Study 32855225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 32855225 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall TIP (all doses)
Number of subjects: 107
Study 35238960 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine 5 mg twice daily for 3 months
Number of subjects: 60
Study 35238960 — intervention group
Group type: COMPARATOR
Intervention: Non-ivabradine group
Number of subjects: 60
Study 32047925 — intervention group
Group type: EXPERIMENTAL
Intervention: Legume supplementation (cowpea or common bean)
Number of subjects: 236
Study 32047925 — intervention group
Group type: EXPERIMENTAL
Intervention: Cowpea or common bean supplementation
Number of subjects: 236
Study 33191588 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus irinotecan
Number of subjects: 452
Study 33191588 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan
Number of subjects: 452
Study 32049551 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish version of the HPV Impact Profile scale (HIP)
Number of subjects: 675
Study 32049551 — intervention group
Group type: EXPERIMENTAL
Intervention: Multigroup analysis according to women's age
Number of subjects: 675
Study 32049551 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmatory analysis of the HIP
Number of subjects: 675
Study 35403228 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning assisted practice after theoretical lesson on cariology
Number of subjects: 53
Study 35403228 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning assisted practice
Number of subjects: 53
Study 32239311 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Strength Training (TST) + High-Intensity Interval Training (HIIT)
Number of subjects: 35
Study 32239311 — intervention group
Group type: COMPARATOR
Intervention: Power Training (PT) + High-Intensity Interval Training (HIIT)
Number of subjects: 35
Study 32239311 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TST and PT
Number of subjects: 35
Study 34949972 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligent heating box
Number of subjects: 200
Study 34949972 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 200
Study 34031056 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg orally once daily)
Number of subjects: 117
Study 34031056 — intervention group
Group type: COMPARATOR
Intervention: Afatinib + Cetuximab (Cetuximab 250 mg/m² on day 15 of cycle 1, then every 2 weeks at 500 mg/m² for 6 months)
Number of subjects: 117
Study 34031056 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Afatinib vs Afatinib + Cetuximab)
Number of subjects: 117
Study 34031056 — intervention group
Group type: COMPARATOR
Intervention: Afatinib + Cetuximab
Number of subjects: 117
Study 34031056 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR gene mutation allele frequency in circulating tumor DNA
Number of subjects: 117
Study 34289052 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32807092 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-duration antibiotic therapy (7 days) after catheter removal
Number of subjects: 185
Study 32807092 — intervention group
Group type: COMPARATOR
Intervention: Long-duration antibiotic therapy (≥14 days)
Number of subjects: 185
Study 36067617 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide-dexamethasone (Rd)
Number of subjects: 119
Study 36067617 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 119
Study 36067617 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 119
Study 33293152 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressor administration (N = 16)
Number of subjects: 52
Study 33293152 — intervention group
Group type: COMPARATOR
Intervention: No vasopressor administration (N = 36)
Number of subjects: 52
Study 33293152 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose vitamin C (HDVC) administration
Number of subjects: 52
Study 33293152 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% albumin (Alb) administration
Number of subjects: 52
Study 33291053 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral parenteral nutrition (P‐PN) including lipid emulsion (17% SMOFlipid® lipid)
Number of subjects: 72
Study 33291053 — intervention group
Group type: COMPARATOR
Intervention: 10% glucose (control)
Number of subjects: 72
Study 33080839 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly high-dose oral vitamin D supplementation
Number of subjects: 20
Study 33080839 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily high-dose oral vitamin D supplementation
Number of subjects: 20
Study 33080839 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 34498980 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine Gel (0.05%)
Number of subjects: 28
Study 34498980 — intervention group
Group type: COMPARATOR
Intervention: Placebo Gel
Number of subjects: 28
Study 35577176 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive Parenting (RP) intervention
Number of subjects: 212
Study 35577176 — intervention group
Group type: COMPARATOR
Intervention: Control (child safety)
Number of subjects: 212
Study 35432382 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Number of subjects: 1882
Study 35432382 — intervention group
Group type: COMPARATOR
Intervention: Teriflunomide
Number of subjects: 1882
Study 35432382 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline sNfL
Number of subjects: 1882
Study 35432382 — intervention group
Group type: EXPERIMENTAL
Intervention: Low baseline sNfL
Number of subjects: 1882
Study 32467054 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopy (RL)
Number of subjects: 369
Study 32467054 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopy (CL)
Number of subjects: 369
Study 35379402 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counselling
Number of subjects: 46
Study 35379402 — intervention group
Group type: COMPARATOR
Intervention: Normal protocol (control group)
Number of subjects: 46
Study 33223484 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (150 min of moderate activity and two sessions of resistance training/week)
Number of subjects: 106
Study 33223484 — intervention group
Group type: COMPARATOR
Intervention: Control group (inactive patients)
Number of subjects: 106
Study 35925745 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive Treatment (ST)
Number of subjects: 100
Study 35925745 — intervention group
Group type: COMPARATOR
Intervention: Supportive-Expressive Treatment (SET)
Number of subjects: 100
Study 32450921 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care supported by a reminder app (Arm A)
Number of subjects: 168
Study 32450921 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone (Arm B)
Number of subjects: 168
Study 33483119 — intervention group
Group type: EXPERIMENTAL
Intervention: eBody Project (6-week online intervention)
Number of subjects: 372
Study 33483119 — intervention group
Group type: COMPARATOR
Intervention: Education brochure (control condition)
Number of subjects: 372
Study 35980389 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide monotherapy
Number of subjects: 0
Study 35980389 — intervention group
Group type: COMPARATOR
Intervention: Active surveillance
Number of subjects: 0
Study 32160416 — intervention group
Group type: EXPERIMENTAL
Intervention: 36.25 Gy in 5 fractions delivered every other day (EOD, arm A, n = 84)
Number of subjects: 170
Study 32160416 — intervention group
Group type: EXPERIMENTAL
Intervention: 36.25 Gy in 5 fractions delivered once a week (QW, arm B, n = 86)
Number of subjects: 170
Study 32160416 — intervention group
Group type: COMPARATOR
Intervention: Both arms (EOD and QW)
Number of subjects: 170
Study 33832998 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-VA acute care alert received
Number of subjects: 565
Study 33832998 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 565
Study 33832998 — intervention group
Group type: EXPERIMENTAL
Intervention: Majority of care received is non-VA
Number of subjects: 565
Study 33832998 — intervention group
Group type: EXPERIMENTAL
Intervention: Private insurance
Number of subjects: 565
Study 33832998 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher income
Number of subjects: 565
Study 33028197 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (TCI Cet 0.48 ng ml‐1)
Number of subjects: 70
Study 33028197 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine in sufentanil-based anaesthesia
Number of subjects: 70
Study 35472561 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol coated polymer free ultra-thin strut sirolimus-eluting stent (PF-SES)
Number of subjects: 70
Study 35472561 — intervention group
Group type: COMPARATOR
Intervention: Biodegradable polymer sirolimus-eluting stent (BP-SES)
Number of subjects: 70
Study 35472561 — intervention group
Group type: EXPERIMENTAL
Intervention: Both stents (PF-SES and BP-SES)
Number of subjects: 70
Study 33462485 — intervention group
Group type: EXPERIMENTAL
Intervention: Host genetic variation regarding microbial taxa
Number of subjects: 18340
Study 33462485 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggestive associations with microbial taxa
Number of subjects: 18340
Study 33462485 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiome trait loci
Number of subjects: 18340
Study 35183892 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin infusion (1 ng/kg/min)
Number of subjects: 80
Study 35183892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 35183892 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin infusion
Number of subjects: 80
Study 35183892 — intervention group
Group type: COMPARATOR
Intervention: Prostacyclin infusion and Placebo
Number of subjects: 80
Study 33638051 — intervention group
Group type: EXPERIMENTAL
Intervention: HiFlow/CWC
Number of subjects: 65
Study 33638051 — intervention group
Group type: EXPERIMENTAL
Intervention: iRoot SP/CWC
Number of subjects: 65
Study 33638051 — intervention group
Group type: EXPERIMENTAL
Intervention: iRoot SP/SC
Number of subjects: 65
Study 33638051 — intervention group
Group type: EXPERIMENTAL
Intervention: HiFlow/SC
Number of subjects: 65
Study 33638051 — intervention group
Group type: COMPARATOR
Intervention: AH Plus/CWC
Number of subjects: 65
Study 35144596 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin (100 mg/qd)
Number of subjects: 140
Study 35144596 — intervention group
Group type: COMPARATOR
Intervention: Metformin (1000 mg/bid)
Number of subjects: 140
Study 33471579 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD) therapy
Number of subjects: 0
Study 33471579 — intervention group
Group type: COMPARATOR
Intervention: No ICD therapy
Number of subjects: 0
Study 35699959 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile instant messaging-delivered brief motivational interviewing
Number of subjects: 161